1y return+217.1%S&P 500 +20.9%
3y return+301.7%S&P 500 +68.5%
5y return+365.7%S&P 500 +74.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2019: $397 against $232 in the S&P 500.2
Fairmount Funds Management LLCS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| ORKAOruka Therapeutics Inc | $352.6M | 23.3% | |
| DNTHDianthus Therapeutics Inc | $247.3M | 16.3% | |
| Damora Therapeutics IncCUSIP 36322Q206 | $226.6M | 15.0% | |
| COGTCogent Biosciences Inc | $213.0M | 14.1% | |
| JBIOJade Biosciences Inc | $101.2M | 6.7% | |
| ELVNEnliven Therapeutics Inc | $94.2M | 6.2% | |
| VRDNViridian Therapeutics Inc | $93.5M | 6.2% | +30.1% |
| ZBIOZenas Biopharma Inc | $59.9M | 4.0% | |
| Crescent Biopharma Inc.CUSIP G2545C104 | $49.5M | 3.3% | |
| Apogee Therapeutics IncCUSIP 03770N101 | $39.6M | 2.6% | |
| FTHFaeth Therapeutics Inc | $18.1M | 1.2% | New |
| IKTInhibikase Therapeutics Inc | $17.5M | 1.2% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| DNTHDianthus Therapeutics Inc | September 30, 2023 | +613.1% | $247.3M |
| Apogee Therapeutics IncCUSIP 03770N101 | September 30, 2023 | +523.1% | $39.6M |
| ORKAOruka Therapeutics Inc | September 30, 2024 | +288.3% | $352.6M |
| COGTCogent Biosciences Inc | December 31, 2020 | +244.6% | $213.0M |
| ELVNEnliven Therapeutics Inc | March 31, 2023 | +131.7% | $94.2M |
| JBIOJade Biosciences Inc | June 30, 2025 | +122.4% | $101.2M |
| ZBIOZenas Biopharma Inc | September 30, 2024 | +50.0% | $59.9M |
| Crescent Biopharma Inc.CUSIP G2545C104 | June 30, 2025 | +11.5% | $49.5M |
| VRDNViridian Therapeutics Inc | March 31, 2021 | +9.9% | $93.5M |
| Damora Therapeutics IncCUSIP 36322Q206 | March 31, 2026 | +0.4% | $226.6M |
Sold off last quarter
- SYRESpyre Therapeutics Inc was $202.7M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +32.2% | +14.8% |
| March 31, 2026 | +22.9% | −4.6% |
| December 31, 2025 | +51.6% | +2.4% |
| September 30, 2025 | +28.7% | +7.8% |
| June 30, 2025 | +4.1% | +10.5% |
| March 31, 2025 | −13.4% | −4.6% |
| December 31, 2024 | −18.9% | +2.1% |
| September 30, 2024 | +24.9% | +5.4% |
| June 30, 2024 | −5.5% | +4.0% |
| March 31, 2024 | +24.5% | +10.0% |
| December 31, 2023 | +29.2% | +11.2% |
| September 30, 2023 | −8.7% | −3.6% |
| June 30, 2023 | +10.6% | +8.3% |
| March 31, 2023 | −11.5% | +7.0% |
| December 31, 2022 | +28.4% | +7.1% |
| September 30, 2022 | +21.8% | −5.3% |
| June 30, 2022 | −16.7% | −16.5% |
| March 31, 2022 | −7.2% | −4.9% |
| December 31, 2021 | +2.0% | +10.7% |
| September 30, 2021 | −4.0% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Fairmount Funds Management LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1802528&type=13F-HR&dateb=&owner=include&count=40CIK 1802528
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1802528/000110465926096405/Filed August 14, 2026 · accession 0001104659-26-096405